J. H. Beijnen

发表

J. Beijnen, A. Huitema, T. Dorlo, 2023 .

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Willem Boogerd, Jos H Beijnen, J. Beijnen, 2004, Cancer treatment reviews.

Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H. Rosing, J. Beijnen, A. Huitema, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin

J. Schellens, J. Hasselt, J. Beijnen, 2015, CPT: pharmacometrics & systems pharmacology.

Inherent formulation issues of kinase inhibitors.

J. Schellens, B. Nuijen, M. Herbrink, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

J. Schellens, J. Beijnen, B. Nuijen, 2016, Cancer treatment reviews.

DNA-based drug interactions of cisplatin.

J. Schellens, J. Beijnen, R. V. van Waardenburg, 2002, Cancer treatment reviews.

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

H. Hansen, J. Verweij, H. Rosing, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

J. Schellens, J. Beijnen, M. Joerger, 2004, Methods and findings in experimental and clinical pharmacology.

A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices.

H. Rosing, J. Beijnen, H. Guchelaar, 2020, Biomedical chromatography : BMC.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction

I. Meijerman, S. Harmsen, J. H. Beijnen, 2008, Drug Metabolism and Disposition.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor Mediated Cyp3a4 Induction Dmd #17335 2 Ls180 as a Model to Study Cyp3a4 Induction

I. Meijerman, S. Harmsen, J. H. Beijnen, 2022 .

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

J. Schellens, H. Rosing, J. Beijnen, 2008, Analytical and bioanalytical chemistry.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1990, Journal of pharmaceutical and biomedical analysis.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

J. Beijnen, J. Schellens, D. Pluim, 1999, Analytical biochemistry.

Ciprofloxacin Strongly Inhibits Clozapine Metabolism

J. Schellens, J. Beijnen, M. Söhne, 2009, Clinical Drug Investigation.

The functional role of P-glycoprotein in the blood-brain barrier.

J. Beijnen, O. van Tellingen, O. Tellingen, 1997, Journal of pharmaceutical sciences.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

I. Meijerman, S. Harmsen, R. Maas-Bakker, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. V. Hasselt, L. Heyns, K. Calsteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

H. Rosing, J. Beijnen, J. Lieverst, 2002, British Journal of Cancer.

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53

J. Beijnen, M. V. van Velthuysen, J. Schellens, 2015, British Journal of Cancer.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetically Guided Administration of Chemotherapeutic Agents

J. Schellens, J. Beijnen, R. Mathôt, 2000, Clinical pharmacokinetics.

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

J. Beijnen, W. Boogerd, E. Kemper, 2004, Cancer Chemotherapy and Pharmacology.

Development and Manufacture of Diacetylmorphine/Caffeine Sachets for Inhalation Via ‘Chasing the Dragon’ by Heroin Addicts

W. van den Brink, J. Beijnen, B. Nuijen, 2004, Drug development and industrial pharmacy.

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

T. Schumacher, J. Beijnen, J. Haanen, 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

D. Richel, J. Schellens, H. Rosing, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

J. Schellens, H. Rosing, J. Beijnen, 2004, Cancer Chemotherapy and Pharmacology.

From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies

A. Schinkel, O. Tellingen, J. H. Beijnen, 2012, Journal of clinical pharmacology.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

H. Rosing, N. Steeghs, N. de Vries, 2024, Therapeutic drug monitoring.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of pharmaceutical and biomedical analysis.

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

J. Schellens, J. Beijnen, I. Meijerman, 2012, Molecular Diagnosis & Therapy.

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer

J. Beijnen, A. Huitema, J. Schellens, 2006, British Journal of Cancer.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Schornagel, M. Schot, H. Helgason, 2006, British Journal of Cancer.

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

J. Wanders, J. Schellens, J. Beijnen, 2013, Investigational New Drugs.

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2004, Analytical biochemistry.

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

J. Schellens, J. Beijnen, R. Mathijssen, 2015, British journal of clinical pharmacology.

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

S. Linn, J. Schellens, H. Rosing, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

H. Rosing, J. Beijnen, A. Schinkel, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The pharmacological role of P-glycoprotein in the intestinal epithelium.

J. Beijnen, O. van Tellingen, O. Tellingen, 1998, Pharmacological research.

Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy

S. Rodenhuis, A. Huitema, M. E. Jonge, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Anti-cancer drugs.

Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.

J. Schellens, J. D. de Vos, N. Vries, 2015, Veterinary and comparative oncology.

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2007, International archives of occupational and environmental health.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2001, British journal of clinical pharmacology.

Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry: Validation and Application in Routine Therapeutic Drug Monitoring

J. Schellens, H. Rosing, J. Beijnen, 2013, Therapeutic drug monitoring.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, M. Hillebrand, 2013, Biomedical chromatography : BMC.

Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites

H. Rosing, J. Beijnen, W. Niessen, 2021 .

The use of the Calvert formula to determine the optimal carboplatin dosage

S. Rodenhuis, J. Beijnen, R. Maes, 2005, Journal of Cancer Research and Clinical Oncology.

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

S. Rodenhuis, J. Beijnen, A. Huitema, 2008, Cancer Chemotherapy and Pharmacology.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

H. Rosing, J. Beijnen, N. Venekamp, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

J. Wanders, J. Schellens, J. Beijnen, 2011, The AAPS Journal.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

J. Baars, J. Beijnen, A. Huitema, 2010, Human antibodies.

Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.

H. Rosing, J. Beijnen, A. Huitema, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen

S. Linn, J. Schellens, H. Rosing, 2014, Breast Cancer Research and Treatment.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

J. Wanders, E. Raymond, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error

A. Huitema, J. G. Hasselt, J. H. Beijnen, 2014, Investigational New Drugs.

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

J. Beijnen, J. Haanen, K. Oosterhuis, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

H. Keizer, J. Schellens, J. Beijnen, 2000, British journal of clinical pharmacology.

Ultra‐sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma for a microdose clinical trial

J. H. Beijnen, J. Schellens, H. Rosing, 2018, Journal of pharmaceutical and biomedical analysis.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

J. Schellens, J. Beijnen, J. D. de Vos, 2015, Veterinary and comparative oncology.